Outcomes of age-based and precision screening compared with no screening.

Outcomes of age-based and precision screening compared with no screening.</p

Model parameters.

Model parameters.</p

Incremental cost and QALYs of precision and age-based screening compared with no screening.

Results based on 10,000 simulations. The solid lines describe the incremental costs incurred and QALYs gained of precision screening versus no screening, whilst the dashed lines represent the incremental costs and QALYs of age-based versus no screening. QALY, quality-adjusted life-year.</p

Overdiagnosed cases and prostate cancer deaths prevented with precision screening as compared to age-based screening.

Results based on 10,000 simulations.</p

Table S1, Table S2, and Supplementary Note from Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk

Table S1, Table S2, and Supplementary Note, which includes PIs from the PRACTICAL, CRUK, BPC3, CAPS, PEGASUS consortia, and Funding Acknowledgements</p

Correlation between relative TL of unaffected men in IMPACT set (n = 644) and age at blood-draw (r = −0.164, p<0.001).

<p>Correlation between relative TL of unaffected men in IMPACT set (n = 644) and age at blood-draw (r = −0.164, p<0.001).</p

Hazard ratios for prostate cancer in the IMPACT study, (Cox regression analyses) and for breast cancer in the RMH study, (weighted retrospective Cox regression analyses), by <i>BRCA1/2</i> mutation status.

<p>Hazard ratios for prostate cancer in the IMPACT study, (Cox regression analyses) and for breast cancer in the RMH study, (weighted retrospective Cox regression analyses), by <i>BRCA1/2</i> mutation status.</p

Correlation between relative TL in unaffected women in the RMH Carrier Clinic set (n = 159) and age at blood-draw (r = −0.126, p = 0.078).

<p>Correlation between relative TL in unaffected women in the RMH Carrier Clinic set (n = 159) and age at blood-draw (r = −0.126, p = 0.078).</p

Association between <i>BRCA1</i> or <i>BRCA2</i> mutation status and mean relative TL in the IMPACT study, adjusting for age and smoking status, and in the RMH Carrier Clinic Set, adjusting for age.

<p>Association between <i>BRCA1</i> or <i>BRCA2</i> mutation status and mean relative TL in the IMPACT study, adjusting for age and smoking status, and in the RMH Carrier Clinic Set, adjusting for age.</p

Characteristics of IMPACT and RMH Carrier Clinic recruits.

<p>Characteristics of IMPACT and RMH Carrier Clinic recruits.</p